Drug Approval | December 18, 2025
FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Patients with BRCA mutations often face aggressive disease and poor prognosis
Patients with BRCA mutations often face aggressive disease and poor prognosis
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Ryght AI tackles these hurdles with its AI Site Twin platform
Subscribe To Our Newsletter & Stay Updated
